Drugs / AAVCAGsCD59
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03585556 | Sep 2018 → Jan 2020 | wet macular degeneration | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03144999 | Mar → Dec 2017 | dry age related macular degeneration | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05811351 | Mar 2023 → Feb 2026 | diffuse secondary choroid atrophy | Janssen Research & Development, LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06635148 Background | Sep 2024 → Aug 2029 expected | diffuse secondary choroid atrophy, macular degeneration | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT04358471 Comparator | Jul 2021 → Jul 2023 | diffuse secondary choroid atrophy, dry age related macular degeneration | Hemera Biosciences | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVCAGsCD59 | “JNJ-81201887 (AAVCAGsCD59)” NCT06635148 ↗ |
| Known as | JNJ-81201887 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06635148 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated viral vector serotype 2 (AAVCAGsCD59)” NCT03585556 ↗ |
| Route | Intravitreal | “AAVCAGsCD59 is administered as a single intravitreal injection in an office setting” NCT03144999 ↗ |
| Target | CD59 | “causes normal retinal cells to increase the expression of a soluble form of CD59 (sCD59)” NCT03144999 ↗ |